OX1, a key drug compound that was developed by Dr. Daniel Chain while heading the Israeli company Mindset BioPharmaceuticals, protects nerve cells from highly oxidizing neurotoxins. OX1 is treating Friedreich’s Ataxia and may be used for other neuro-degenerative diseases.
http://www.prnewswire.com/news-releases/viropharma-licenses-rights-from-intellect-neurosciences-for-product-candidate-for-friedreichs-ataxia-130841723.html